Biocon manufactures generic active pharmaceutical ingredients for the treatment of cancer and autoimmune diseases...
Read moreBiocon manufactures generic active pharmaceutical ingredients for the treatment of cancer and autoimmune diseases...
Read moreAnnual Revenue
$1.2B
Biocon's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 3.3B. Over the last four quarters, Biocon's revenue has grown by 2.2%. Specifically, in Q4 2021's revenue was $298.4M; in Q1 2022, it was $306.3M; in Q2 2022, it was $281.1M; in Q3 2022, Biocon's revenue was $291.9M.